摘要
铂类药物广泛应用于多种实体瘤的治疗,耐药是导致治疗失败最主要的因素之一。铜离子转运体(copper transporter 1,CTR1)是铜离子的特异性转运体,主要位于细胞膜,负责将铜离子泵入细胞。CTR1也是铂类药物的主要转运体,在铂类药物耐药的发生中起重要的作用。CTR1的表达量、基因多态性及降解均会影响铂类药物耐药,因此其可能成为预测铂类药物耐药的生物标志分子和克服铂类药物耐药的新靶标。
Platinum drugs are widely used in the treatment of various solid tumors, but their resistance to platinum is the most significant obstacle to successful treatment. Copper transporter 1 (CTR1) is the specific transporter for copper, and it mainly locates at the plasma membrane and plays a role in pumping copper into the cell. CTR1 is also the major platinum influx transporter and plays a key role in platinum resistance. Th e expression, polymorphism, and degradation of CTR1 aff ect platinum resistance in tumors. Th erefore, CTR1 may be a potential predictive biomarker of platinum resistance and a therapeutic target for overcoming platinum resistance.
作者
欧阳倩颖
刘玉洁
刘英姿
OUYANG Oianying;LIU Yujie;LIU Yingzi(Department of Clinical Pharmacology,Xiangya Hospital,Central South University,Changsha 410008;2.Institute of Clinical Pharmacology,Central South University,Hunan Key Laboratory of Pharmacogenetics,Changsha 410078,China)
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2018年第12期1376-1379,共4页
Journal of Central South University ：Medical Science
基金
国家自然科学基金(81402968)
湖南省自然科学基金(2017JJ3503)
中南大学研究生科研创新项目(2017zzts862).
关键词
铜离子转运体
铂类药物
耐药性
copper transporter 1
platinum drugs
drug resistance
